Print

AstraZeneca PLC (AZN) Release: New PLATO Sub-Analysis Suggests Patients’ Age Had No Impact on Study Finding of a Greater Reduction in Thrombotic Cardiovascular Events With BRILINTA (ticagrelor) Compared to Clopidogrel  
9/24/2012 10:11:54 AM

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced results from a sub-analysis of PLATO that evaluated the effects of age on clinical outcomes in patients with acute coronary syndrome (ACS). Results of this analysis suggest the overall findings from the PLATO study of a greater reduction in thrombotic cardiovascular (CV) events with BRILINTA® (ticagrelor) tablets plus aspirin compared to clopidogrel plus aspirin were consistent regardless of age. These data are now published in the September print and online issues of Circulation: Cardiovascular Quality and Outcomes, and were presented at the American College of Cardiology 2011 meeting.
//-->